Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.71
-2.3%
$1.70
$1.40
$7.88
$75.91M1.56338,867 shs35,978 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$10.55
-7.9%
$10.28
$4.11
$28.68
$69.42M2.97172,935 shs96,634 shs
Geron Corporation stock logo
GERN
Geron
$1.32
-4.3%
$1.44
$1.17
$5.06
$840.73M0.6411.28 million shs7.54 million shs
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$10.85
+4.3%
$10.50
$0.29
$3.72
$460.79M3.931.22 million shs6.15 million shs
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
$16.24
$16.23
$7.15
$16.26
$531.75M2.36114,469 shsN/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
+2.34%+0.86%+2.34%+10.76%-66.60%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-8.25%-17.09%-6.53%+118.10%+56,027.45%
Geron Corporation stock logo
GERN
Geron
-4.17%-3.16%-13.75%0.00%-70.00%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
+6.34%+40.35%+50.72%+158.71%+18.99%
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.3722 of 5 stars
2.02.00.00.00.62.51.3
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.3546 of 5 stars
3.54.00.00.03.31.70.6
Geron Corporation stock logo
GERN
Geron
3.5396 of 5 stars
3.32.00.01.32.61.70.6
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.0016.96% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00478.20% Upside
Geron Corporation stock logo
GERN
Geron
2.60
Moderate Buy$4.61249.33% Upside
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00
N/AN/AN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EPIX, UMRX, GERN, FBRX, and UROV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Geron Corporation stock logo
GERN
Geron
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$1.00
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
5/8/2025
Geron Corporation stock logo
GERN
Geron
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.50
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Geron Corporation stock logo
GERN
Geron
$116.29M7.23N/AN/A$0.46 per share2.87
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$22.50M20.48N/AN/A$1.04 per share10.43
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/A($1.90) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)
Geron Corporation stock logo
GERN
Geron
-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/A

Latest EPIX, UMRX, GERN, FBRX, and UROV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q3 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.2430N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
5/7/2025Q1 2025
Geron Corporation stock logo
GERN
Geron
-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
67.15
67.15
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22
Geron Corporation stock logo
GERN
Geron
0.44
7.87
6.97
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.18
2.90
2.90
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/A
2.91
2.91

Institutional Ownership

CompanyInstitutional Ownership
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Geron Corporation stock logo
GERN
Geron
73.71%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
26.39%
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
18.44%

Insider Ownership

CompanyInsider Ownership
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
Geron Corporation stock logo
GERN
Geron
7.42%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
31.50%
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable
Geron Corporation stock logo
GERN
Geron
70636.92 million589.66 millionOptionable
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
7242.47 millionN/ANot Optionable
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
7032.74 millionN/ANot Optionable

Recent News About These Companies

OC Drugmakers Cut Headcounts, Close Offices
A2 Bio’s new CEO aims to grow platform
C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More
HEALTH BEHAVIOR AND NUTRITION SCIENCES
Bulletin Science and Security Board
Marine Sciences & Technology
The 7 Best Science Kits for Kids and Teens
Careers in Computer Science
PhD in Information Science
Core Requirements & Courses
Inspiring Women in Science

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.71 -0.04 (-2.29%)
Closing price 04:00 PM Eastern
Extended Trading
$1.72 +0.01 (+0.58%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$10.55 -0.90 (-7.86%)
Closing price 04:00 PM Eastern
Extended Trading
$10.68 +0.13 (+1.18%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Geron stock logo

Geron NASDAQ:GERN

$1.32 -0.06 (-4.35%)
Closing price 04:00 PM Eastern
Extended Trading
$1.32 0.00 (0.00%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Urovant Sciences stock logo

Urovant Sciences NASDAQ:UROV

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.